Article Sidebar
Keywords:
clinical spectrum cost implication HIV-infected children district hospital
Article Details
Issue
Section
Articles
By submitting manuscripts to SAFP, authors of original articles are assigning copyright to the SA Academy of Family Practice/Primary Care. Copyright of review articles are assigned to the Publisher, Medpharm Publications (Pty) Ltd, unless otherwise specified. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAFP for educational and research purposes without obtaining permission.
Main Article Content
The Clinical Spectrum and Financial Burden of HIV Infected Children in a Regional Hospital in South Africa
Abstract
Background: HIV infection has become a common risk factor for hospital admission and a major contributor to childhood morbidity in South Africa.
There remains a paucity of data describing the cost of hospitalisation of HIV-infected children in South Africa. The aim of this study was to describe
basic demographics and clinical patterns as well as cost implications of the hospitalisation of HIV-infected children in the Karl Bremer Hospital,
Cape Town, South Africa.
Methods: A prospective descriptive longitudinal study of HIV-positive paediatric admissions, matched with HIV-negative controls, was conducted.
Patients were matched according to age, socio-demographic area and presenting symptoms. Questionnaires were used to elicit demographic and
clinical information. Worksheets were used to record any costs incurred, which were calculated at rates applicable to 2001. This was done daily
during admission. Data was statistically analysed in MS Excel and MS Access. Thirty HIV-positive children were identified, of which 23 could be
matched with 23 HIV-negative children. HIV-positive children had a higher admission rate (2.09 versus 0.26 previous admissions, p = 0.000) and
were also younger at the time of first admission to hospital (7.52 versus 13.78 months, p = 0.005). There is a statistically significant difference in
duration of hospitalisation in the HIV-positive group when compared to the control group – duration of hospitalisation being longer in the HIV-positive
group (7.91 versus 4.96 days, p = 0.005). Despite being treated for the same condition, there is a statistically significant difference in the cost
incurred by children in the HIV-positive group (R6 203.16) when compared to the HIV-negative group (R3 901.96); p = 0.000.
Conclusion: This study shows a clear and statistically significant difference between the HIV-positive group and HIV-negative control group of
children with regard to admission rate, age at first admission, duration of hospitalisation and cost incurred during hospitalisation. HIV-infected
children in the pre-HAART (highly active anti-retroviral therapy) era were hospitalised more frequently and for longer periods than their HIV-uninfected counterparts. These findings seem to suggest that the cost of hospitalising HIV-positive children is significantly more than HIV-negative controls, which will increase the financial burden on already restricted health resources.
There remains a paucity of data describing the cost of hospitalisation of HIV-infected children in South Africa. The aim of this study was to describe
basic demographics and clinical patterns as well as cost implications of the hospitalisation of HIV-infected children in the Karl Bremer Hospital,
Cape Town, South Africa.
Methods: A prospective descriptive longitudinal study of HIV-positive paediatric admissions, matched with HIV-negative controls, was conducted.
Patients were matched according to age, socio-demographic area and presenting symptoms. Questionnaires were used to elicit demographic and
clinical information. Worksheets were used to record any costs incurred, which were calculated at rates applicable to 2001. This was done daily
during admission. Data was statistically analysed in MS Excel and MS Access. Thirty HIV-positive children were identified, of which 23 could be
matched with 23 HIV-negative children. HIV-positive children had a higher admission rate (2.09 versus 0.26 previous admissions, p = 0.000) and
were also younger at the time of first admission to hospital (7.52 versus 13.78 months, p = 0.005). There is a statistically significant difference in
duration of hospitalisation in the HIV-positive group when compared to the control group – duration of hospitalisation being longer in the HIV-positive
group (7.91 versus 4.96 days, p = 0.005). Despite being treated for the same condition, there is a statistically significant difference in the cost
incurred by children in the HIV-positive group (R6 203.16) when compared to the HIV-negative group (R3 901.96); p = 0.000.
Conclusion: This study shows a clear and statistically significant difference between the HIV-positive group and HIV-negative control group of
children with regard to admission rate, age at first admission, duration of hospitalisation and cost incurred during hospitalisation. HIV-infected
children in the pre-HAART (highly active anti-retroviral therapy) era were hospitalised more frequently and for longer periods than their HIV-uninfected counterparts. These findings seem to suggest that the cost of hospitalising HIV-positive children is significantly more than HIV-negative controls, which will increase the financial burden on already restricted health resources.
